Status:
UNKNOWN
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.
Conditions:
Relapsed or Refractory B-cell Hematologic Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies
Eligibility Criteria
Inclusion
- Age is over 18 years old
- Histologically or cytologically diagnosed patients with recurrent or refractory B-cell malignancies
- ECOG performance status (PS) 0 \~ 1
- Expected survival of \> or = 3 months
Exclusion
- The use of PI3Ks as the target of anti-tumor drugs progress (due to intolerance group)
- Received any other anti-cancer treatment within 4 weeks
- Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors that affect drug use and absorption
- Allergy, or known to have a history of allergy to the drug components
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04865458
Start Date
April 1 2021
End Date
April 1 2024
Last Update
May 6 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
2
Jiangsu Province Hospital
Nanjing, Jiangsu, China